LUYE PHARMA GROUP LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.68 HKD | +1.13% |
|
+0.75% | -28.15% |
| Sales 2024 * | 6.83B 943M 7.38B | Sales 2025 * | 7.81B 1.08B 8.43B | Capitalization | 9.34B 1.29B 10.08B |
|---|---|---|---|---|---|
| Net income 2024 * | 677M 93.49M 731M | Net income 2025 * | 965M 133M 1.04B | EV / Sales 2024 * | 1.75 x |
| Net Debt 2024 * | 2.59B 358M 2.8B | Net Debt 2025 * | 2.41B 333M 2.6B | EV / Sales 2025 * | 1.5 x |
| P/E ratio 2024 * |
14.5
x | P/E ratio 2025 * |
10.9
x | Employees | 5,270 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 51.84% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +1.13% | ||
| 1 week | +0.75% | ||
| 1 month | -3.25% | ||
| 3 months | -7.59% | ||
| 6 months | -30.75% | ||
| Current year | -28.15% |
1 week
2.62
2.74
1 month
2.623.11
Current year
2.343.77
1 year
2.344.00
3 years
1.885.84
5 years
1.887.00
10 years
1.8811.54
| Managers | Title | Age | Since |
|---|---|---|---|
Dian Bo Liu
CEO | Chief Executive Officer | 59 | 03-07-01 |
Rong Bing Yang
PSD | President | 58 | 94-06-07 |
Yun Li Xue
PRN | Corporate Officer/Principal | 60 | 94-06-07 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hui Xian Yuan
BRD | Director/Board Member | 65 | 94-06-07 |
Rong Bing Yang
PSD | President | 58 | 94-06-07 |
Dian Bo Liu
CEO | Chief Executive Officer | 59 | 03-07-01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.58% | 4 M€ | -27.92% | ||
| 0.15% | 2 M€ | -14.14% | ||
| 0.04% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 2.68 | +1.13% | 5,629,500 |
| 24-05-30 | 2.65 | -1.49% | 15,524,000 |
| 24-05-29 | 2.69 | -0.74% | 6,810,500 |
| 24-05-28 | 2.71 | +0.37% | 5,532,000 |
| 24-05-27 | 2.7 | +1.50% | 6,712,000 |
Delayed Quote Hong Kong S.E., May 31, 2024 at 04:08 am EDT
More quotes
Luye Pharma Group Ltd. is an investment holding company principally engaged in the development, production, marketing and sale of pharmaceutical products. Along with subsidiaries, the Company operates its business through four segments: the Oncology Drugs segment, the Cardiovascular System Drugs segment, the Alimentary Tract and Metabolism Drugs segment and the Others segment. The Companyâs main products include paclitaxe for chemotherapy treatment of cancer, sodium glycididazole for radiotherapy for solid tumours, Chinese medicine for treatment of hypercholesterolaemia, and Rivastigmine Transdermal Patches for treatment of Alzheimerâs disease and dementia, among others. The products are sold under the name of Lipusu, CMNa, Xuezhikang, Maitongna ,and Bei X. Through its subsidiaries, the Company is also engaged in the provision of contract research and process development. The Company operates its business mainly in Mainland China.
Sector
Pharmaceuticals
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
2.482
CNY
Average target price
2.822
CNY
Spread / Average Target
+13.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -28.15% | 1.29B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B |
- Stock Market
- Equities
- 2186 Stock
